Compare Cassava Sciences Inc (FLNA) vs Medtronic PLC (MDT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Medtronic PLC — how do they compare? Cassava Sciences Inc trades at $0.82 (market cap $39.40M), while Medtronic PLC trades at $87.92 (market cap $112.24B). The key difference: Medtronic PLC is far larger — about 2848.7× Cassava Sciences Inc's market cap, and Medtronic PLC pays a 3.28% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cassava Sciences Inc for 37 Days and Medtronic PLC for 63 Days on average.
| FLNA | MDT | |
|---|---|---|
Market Cap | $39.40M | $112.24B |
Volume | 759,018 | 105,663,236 |
Sector | Health | Health |
52-Week High | $4.64 | $105.35 |
52-Week Low | $0.68 | $73.75 |
Typical Hold Time | 37 Days | 63 Days |
Enterprise Value | -$43.28M | $131.58B |
Dividend Yield | — | 3.28% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.8157, down 6.77% today, with a bearish technical signal from moving averages. The company shows improving quarterly EPS trends, beating expectations in recent quarters, though it remains unprofitable with negative ROE and ROA. Recent FDA clearance for its epilepsy drug trial provides a positive catalyst. Analyst sentiment is bullish with 67% buy ratings.
The outlook hinges on clinical progress; upside exists if Phase 2a trials succeed, but high cash burn and lack of revenue pose significant risks. Investors should weigh the strong analyst support against the company's financial challenges and binary clinical outcomes.
Medtronic (MDT) trades at $85.51, down 1.81% on the day, showing bearish technical signals despite strong fundamental performance. The company has beaten earnings estimates for three consecutive quarters with Q3 2026 results pending, while maintaining robust profitability margins of 65% gross and 14% net. Recent news highlights the company's 49-year dividend growth streak and new product approvals, though technical indicators show selling pressure with the stock trading near support at $85.
MDT presents a compelling value opportunity with a 3.2% dividend yield and 14% upside to the $97.80 consensus target, though near-term technical weakness and increasing debt levels warrant caution. The company's consistent earnings beats and medical device market leadership support long-term growth, while regulatory approvals for new systems provide catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Medtronic PLC
One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →
